This bioactive compound was named candicidin, because of its high activity on Candida albicans. Candicidin is a polyene antifungal antibiotic produced by a strain of Streptomyces griseus. It is especially effective against Candida albicans (more effective than amphotericin B), and is administered intravaginally in the treatment of vulvovaginal candidiasis. Candicidin inhibits cell membrane of Candida albicans, resulting in disruption of membrane integrity and ultimately cell death. There is some evidence that the binding site in the cell wall may be to fatty acids or fatty acid esters and that this binding capacity must be satisfied before candicidin can bring about its lethal effect by binding to sterol in the cell membrane.

Formed as a complex of iodine with undecoylium chloride, undecoylium chloride iodine is a cationic detergent typically used as a topical antigermicidal agent.

Calcium gluceptate (also known as calcium glucoheptonate) was used, as calcium supplements by people who were unable to get enough calcium or who was needed it more. This drug was used to prevent and to treat several conditions, related to the hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones; it is also needed for the heart, muscles, and nervous system to work properly. Nevertheless, that use of calcium gluceptate was discontinued.

Carbomycin is a complex mixture containing carbomycin A with a small portion of carbomycin B. Carbomycin is produced by Streptomyces halstedii and acts as an antibiotic. The drug was approved by FDA under the name Magna-terramycin (in combination with oxytetracycline) for the treatment of bacterial chronic respiratory diseases in chickens. Carbomycin exerts its antibacterial action by binding within the large ribosomal subunit and thus inhibiting the protein synthesis in bacterias.

Ergoloid mesylates (USAN), co-dergocrine mesilate (BAN) or dihydroergotoxine mesylate, trade name Hydergine, is a mixture of the methanesulfonate salts of three dihydrogenated ergot alkaloids (dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine). It was developed by Albert Hofmann (the inventor of LSD) for Sandoz (now part of Novartis). Ergoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels. Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.